TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02941848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Study: NCT03343210

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: quality of life and pain measurement .
Description: comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: quality of life and pain measurement .
Description: comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
Study: NCT02682004

Intervention type: OTHER
Intervention: leptin, serotonin and adiponectin level

Intervention type: OTHER
Intervention: leptin,serotonin, adiponectin level
Study: NCT02973802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATX-GD-59
Description: Disease specific immune modulating treatment for Graves Disease
Study: NCT02361177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Study: NCT04418180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral distilled water
Study: NCT02025478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: * A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician.
Study: NCT03924947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Delayed release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Delayed release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Delayed release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Delayed release capsules
Study: NCT01921777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study: NCT04921748

Intervention type: PROCEDURE
Intervention: Neurorehabilitation
Description: All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.

Intervention type: PROCEDURE
Intervention: Neurorehabilitation
Description: All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
Study: NCT03713073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allogenic amnion chorion membrane
Description: Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen dressing
Description: Collagen dressing is used to cover wounds in dental surgery.
Study: NCT03892928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine group
Description: In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
Study: NCT04221022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light physical activity
Description: Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate physical activity
Description: Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vigorous physical activity
Description: Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
Study: NCT00630591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Materials Group
Description: 7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Tailored Intervention
Description: Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
Study: NCT03227978

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PCL mesh pleurodesis
Description: Coverage of the lung surface by PCL mesh
Study: NCT03009019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Active

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DFN-15 Placebo
Study: NCT02194842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ra223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study: NCT00808145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine / Cisplatin / Sorafenib
Description: All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
Study: NCT01522677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT with 5-ALA radiosensitization
Description: Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
Study: NCT04205955

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive healthy living education via phone call

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive diet modification coaching via phone call

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Message
Description: Receive motivational messages via email and/or text message

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Message
Description: Receive motivational messages via email and/or text message

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01836016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (Ventolin®)
Description: According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler®)
Description: According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeijianpi granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeiyishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqizishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional medicine + TCM
Description: Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
Study: NCT01396200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
Study: NCT04567797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laevo 2
Description: The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: backX
Description: backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLx ErgoSkeleton
Description: The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V22 ErgoSkeleton
Description: Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons.
Study: NCT04747210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: contextual one-on-one coaching
Description: Training workshop and coaching one-on-one

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trainig workshop
Description: Ten-hour training workshop.
Study: NCT00616577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
Study: NCT03396211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Fixed dose of nivolumab given intravenously every 2 weeks
Study: NCT02239861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-Specific CTLs
Description: Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
Study: NCT03481556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide (Melflufen)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide (Melflufen)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous infusion
Study: NCT02741713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS Pectoralis 1 and 2 Blocks
Description: An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Interscalene Block
Description: An interscalene block will be performed on the subjects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: An interscalene block will be performed on the subjects.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Block

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Solution for Injection in Interscalene Block
Description: 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution for Injection in Interscalene Block
Description: 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Solution for Injection in Sham Block
Description: Lidocaine 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution for Injection PECS Blocks
Description: 10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
Study: NCT01272323

Intervention type: BIOLOGICAL
Intervention: Placebo
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.

Intervention type: BIOLOGICAL
Intervention: Cat-PAD Dose 1
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.

Intervention type: BIOLOGICAL
Intervention: Cat-PAD Dose 2
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Study: NCT01516853

Intervention type: DEVICE
Intervention: Non-contrast MRI
Description: Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).

Intervention type: DEVICE
Intervention: Non-contrast MRI
Description: Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
Study: NCT00495872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg PO Daily for 28 Days Every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1000 mg PO Daily for 28 Days Every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg PO Daily for 28 Days Every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO Daily for 21 Days Every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 25 mg PO Daily for 21 Days Every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off